C4.4A/LYPD3 Antibody (lupartumab) [PerCP]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28646PCP
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Applications
ELISA, Flow Cytometry, Functional
Label
PerCP (Excitation = 490 nm, Emission = 675 nm)
Antibody Source
Recombinant Monoclonal Human IgG1 Clone # lupartumab
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Summary for C4.4A/LYPD3 Antibody (lupartumab) [PerCP]
Immunogen
LYPD3 / C4.4A
Clonality
Monoclonal
Host
Human
Isotype
IgG1
Applications for C4.4A/LYPD3 Antibody (lupartumab) [PerCP]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: C4.4A/LYPD3
Long Name
Leucine Rich Repeat and Fibronectin Type III Domain Containing 3
Alternate Names
LYPD3, MIG-C4
Gene Symbol
LYPD3
Additional C4.4A/LYPD3 Products
Product Documents for C4.4A/LYPD3 Antibody (lupartumab) [PerCP]
Product Specific Notices for C4.4A/LYPD3 Antibody (lupartumab) [PerCP]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...